Log in to search using one of your social media accounts:

 

Incretin Tied to Better Outcomes in NOCS - Diabetes
Prognosis for T2DM patients with NSTEMI, coronary artery stenosis improves with incretin (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 28, 2017 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

International Harrington Prize in Medicine jointly awarded to three recipients
(University Hospitals Cleveland Medical Center) The fourth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2017 Category: Global & Universal Source Type: news

Diabetes could be a warning sign of pancreatic cancer
Conclusion This study uses a large prescription database to investigate the link between diabetes and pancreatic cancer, looking at the timing of first diabetes prescription and change in drugs prescribed. Among people with type 2 diabetes, diagnosis of pancreatic cancer was linked with recent onset of diabetes or rapidly deteriorating diabetes. This suggests these could both be potential warning signs of hidden pancreatic cancer and indicate the need for more investigations. While diabetes has previously been linked with pancreatic cancer, the nature of the cause and effect relationship remains unclear. It could be that d...
Source: NHS News Feed - January 31, 2017 Category: Consumer Health News Tags: Diabetes Cancer Source Type: news

[Report] Drosophila insulin release is triggered by adipose Stunted ligand to brain Methuselah receptor
Animals adapt their growth rate and body size to available nutrients by a general modulation of insulin–insulin-like growth factor signaling. In Drosophila, dietary amino acids promote the release in the hemolymph of brain insulin-like peptides (Dilps), which in turn activate systemic organ growth. Dilp secretion by insulin-producing cells involves a relay through unknown cytokines produced by fat cells. Here, we identify Methuselah (Mth) as a secretin-incretin receptor subfamily member required in the insulin-producing cells for proper nutrient coupling. We further show, using genetic and ex vivo organ culture exper...
Source: ScienceNOW - September 29, 2016 Category: Science Authors: Renald Delanoue Source Type: news

Two incretin-based drugs linked to increased bile duct disease but not pancreatitis
At least two incretin-based drugs – glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors – do not appear to increase the risk of acute pancreatitis in individuals with diabetes but... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - August 1, 2016 Category: Endocrinology Source Type: news

Monthly News Roundup - July 2016
Injectable Adlyxin FDA-Approved for Type 2 Diabetes The FDA has approved Sanofi’s Adlyxin (lixisenatide), a new once-daily injectable type 2 diabetes medication. Adlyxin is classified as an incretin mimetic/GLP-1 receptor agonist. For... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2016 Category: Pharmaceuticals Source Type: news

Do artificial sweeteners live up to the promise of sweetness without harm? An ongoing clinical study investigates
Scientists suspect that aspartame and other artificial sweeteners can lead to lasting, metabolic disruptions when consumed frequently, by activating specific receptors in the intestine. A clinical study is now enrolling volunteer soda drinkers to test the hypothesis. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - June 2, 2016 Category: Biomedical Science Authors: Geoffrey Shearer Tags: Science News aspartame blood sugar clinical trial diet soda G protein-coupled receptors incretin Laboratory of Chemical Biology and Signal Transduction metabolism study volunteers sweet receptors Thomas Huber Thomas P. Sakmar Source Type: news

No increased heart failure with incretin-based drugs
Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 24, 2016 Category: Science Source Type: news

No increased heart failure with incretin-based drugs
(McGill University) Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study published in the New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2016 Category: Global & Universal Source Type: news

Incretin-Based Diabetes Drugs Not Tied to Heart Failure Hospitalizations (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM Use of incretin-based drugs for type 2 diabetes — including dipeptidyl-peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 analogues — is not associated with increased risk for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 23, 2016 Category: Primary Care Source Type: news

Incretin-based diabetes drugs don’t raise heart failure risk
Incretin-based antidiabetic drugs didn’t raise the risk of hospitalization for heart failure in an international observational study involving 1.5 million patients reported online March 24 in the New... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - March 23, 2016 Category: Endocrinology Source Type: news

GLP-1 and Hormonal Secretion in Posttransplant DiabetesGLP-1 and Hormonal Secretion in Posttransplant Diabetes
The incretin hormone glucagon-like peptide 1 (GLP-1) appears to correct the abnormal secretion of insulin and glucagon in posttransplantation diabetes (PTDM), researchers from Norway and Denmark report. Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 17, 2016 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Source Type: news

New Data Inform but Don't Confirm Incretin Diabetes Drugs SafetyNew Data Inform but Don't Confirm Incretin Diabetes Drugs Safety
Two new studies find that incretin-based drugs for the treatment of type 2 diabetes don't cause pancreatic cancer in the short term, but some may raise the risk of heart failure. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 25, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

New incretin-based medicines will allow weight, diabetes control with a single weekly dose
The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 28, 2015 Category: Science Source Type: news

News from the European Association for the Study for Diabetes (EASD) conference in Stockholm
Women exposed to organic pollutants in early pregnancy have more than four-times increased risk of gestational diabetes New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Stockholm shows that a 10-times increased exposure to organic pollutants in early pregnancy is associated with a 4.4 times increased risk of a pregnant woman developing gestational diabetes. Medical Xpress Pesticide exposure tied to diabetes risk A review of 21 observational studies has investigated the link between exposure to pesticides and diabetes. WebMD 'Youngest' toddler wi...
Source: Society for Endocrinology - September 17, 2015 Category: Endocrinology Source Type: news

Study Suggests Incretin Drugs Don't Cause Pancreatic CancerStudy Suggests Incretin Drugs Don't Cause Pancreatic Cancer
A 7-year Danish population-based study found pancreatic cancer risks elevated for all glucose-lowering agents, not just incretin-based therapies, suggesting that diabetes itself may be the cause. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Incretin-Based Therapies and Cardiovascular DiseaseIncretin-Based Therapies and Cardiovascular Disease
Incretin-based therapies offer another treatment option for patients with type 2 diabetes, and may have a beneficial effect on cardiovascular risk factors. International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Danish Study: No Excess Pancreatitis Risk in Incretin UsersDanish Study: No Excess Pancreatitis Risk in Incretin Users
Researchers found that users of all diabetes drug classes had elevated pancreatitis rates, which became nonsignificant after adjustment for confounders. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 9, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California.(PRWeb December 21, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12409444.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 22, 2014 Category: Pharmaceuticals Source Type: news

Basal Insulin With Incretin GLP-1 Receptor Agonists for T2DMBasal Insulin With Incretin GLP-1 Receptor Agonists for T2DM
These tools can help guide the combined use of basal insulin with GLP-1 receptor agonists. Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Diabetes Drug Litigation Prepares to Discuss Byetta Lawsuits, Claims...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 07, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12376827.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 7, 2014 Category: Pharmaceuticals Source Type: news

New Order Issued in Federal Incretin Mimetic Litigation, Where...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 01, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12363707.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 2, 2014 Category: Pharmaceuticals Source Type: news

California Federal Court Overseeing Byetta Lawsuits, Other Incretin...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer after taking incretin...(PRWeb November 23, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12344447.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 23, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Plaintiffs in Federal Diabetes Drug Litigation...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12318604.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 12, 2014 Category: Pharmaceuticals Source Type: news

Diabetes Drug Claims Near 550 Mark in Incretin Mimetic Litigation,...
The Firm is investigating Byetta lawsuits and other legal claims that allege pancreatic cancer, pancreatitis and thyroid cancer caused by incretin mimetics, a Type 2 diabetes drug class.(PRWeb November 02, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12294498.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 2, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits and other legal claims that allege the use of diabetes drugs called incretin mimetics caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb October 08, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12234584.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 9, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, With New Ruling Issued in Federal...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb September 24, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12196939.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2...(PRWeb September 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12163899.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Establishes Deposition Protocol For...
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb August 10, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12083571.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2014 Category: Pharmaceuticals Source Type: news

Diabetes Drug Eyed as Obesity TreatmentDiabetes Drug Eyed as Obesity Treatment
Already approved for the treatment of diabetes, the incretin mimetic liraglutide is now being investigated as a potential weight-loss drug. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Featured in NEJM Journal Watch: Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis (FREE)
Extract Although not the final word, results of two large studies in BMJ should be reassuring for patients taking exenatide (Byetta) and sitagliptin (Januvia... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 8, 2014 Category: Primary Care Source Type: news

Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms (FREE)
By Joe Elia Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 28, 2014 Category: Primary Care Source Type: news

As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA...
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic...(PRWeb February 13, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11583185.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, as Federal and State Incretin Mimetics...
The Firm is investigating Byetta lawsuits that allege an association between the use of Byetta and pancreatic cancer, as well as pancreatitis and thyroid cancer.(PRWeb January 25, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11521828.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 25, 2014 Category: Pharmaceuticals Source Type: news

The Cardiovascular Safety of Incretin-Based TherapiesThe Cardiovascular Safety of Incretin-Based Therapies
Do controlled trials find that 'gliptins' increase risk for adverse cardiac events? Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Incretin Safety Data to Highlight EASD Meeting
BARCELONA (MedPage Today) -- Researchers are anticipating a deeper dive into data from safety trials of two DPP-4 inhibitors with a focus on diabetes outcomes and complications, including pancreatitis, at this year's European Association for the Study of Diabetes meeting here. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 20, 2013 Category: Endocrinology Source Type: news

Cardiac Risks of Diabetes Drugs a Focus at EASD
BARCELONA (MedPage Today) -- A major focus of the upcoming meeting of the European Association for the Study of Diabetes here will be the risks and benefits of the incretin-based therapies, according to the chair of the program committee. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 19, 2013 Category: Cardiology Source Type: news

Novel Diabetes Drug Effective in Trial (CME/CE)
(MedPage Today) -- The investigational SGLT2 inhibitor empagliflozin lowers HbA1c as well as the widely used DPP-4 inhibitor sitagliptin (Januvia), and may work better than the incretin stimulator among patients with worse disease control, researchers found. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 10, 2013 Category: Endocrinology Source Type: news

Incretin Risks Lack Evidence, Says AACE
(MedPage Today) -- There currently is insufficient evidence of a definitive link between incretin diabetes medications and an increased risk of cancer, according to a consensus statement from the American Association of Clinical Endocrinologists. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 22, 2013 Category: Cardiology Source Type: news

The Safety of Incretin Therapy: Are Barriers Beginning to Fall?
The European Medicines Agency declared in July 2013 that there is no evidence that definitively links incretin-based therapy for type 2 diabetes and pancreatitis or pancreatic cancer. Today, August 2, 2013, there are rumors that the US FDA "concurs." (Source: Consultant Live)
Source: Consultant Live - August 3, 2013 Category: Primary Care Source Type: news

FDA Sides With EMA on Incretin Diabetes DrugsFDA Sides With EMA on Incretin Diabetes Drugs
The FDA agrees with the EMA's recent conclusions that firm data lacks support for an increased risk for pancreatic adverse effects with incretin mimetics. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

EMA Finds No Pancreas Risks with Incretins
(MedPage Today) -- The European Medicines Agency has cleared incretin drugs for type 2 diabetes of an association with pancreatic risks. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 29, 2013 Category: Cardiology Source Type: news

EU agency has no new concerns about incretin diabetes drugs
Current data do not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. (Source: theHeart.org)
Source: theHeart.org - July 26, 2013 Category: Cardiology Source Type: news

EU Agency Has No New Concerns on Incretin Diabetes Drugs EU Agency Has No New Concerns on Incretin Diabetes Drugs
Current data do not confirm recent concerns over an increased risk for pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language:  English Contact:  MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, ...
Source: Merck.com - Research and Development News - July 26, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news

Merck's $5.7 Billion Diabetes Franchise Vulnerable
A retrospective analysis published by the BMJ supports previously published findings that diabetic patients taking drugs which target the incretin system to control their blood sugars are at greater risk for developing pancreatic problems, such as acute pancreatitis and pancreatic cancer. Could certain big pharma manufacturers be vulnerable to a price collapse, should European and U.S. regulators ? whom are now actively reviewing data on adverse events ? move to restrict usage or outright remove these therapies from the market due to questionable safety? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 23, 2013 Category: Pharmaceuticals Authors: YCharts Source Type: news

"Breakthrough" Incretin Mimetic Drugs May Cause Pancreatic...
New website offers information about the startling link between incretin mimetics, which are used to treat type two diabetes, and serious illnesses such as renal insufficiency and pancreatic cancer.(PRWeb July 07, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10895062.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 9, 2013 Category: Pharmaceuticals Source Type: news

More Calls for More Research on Incretin Diabetes DrugsMore Calls for More Research on Incretin Diabetes Drugs
The Endocrine Society is the latest organization to call for more research into incretin-based therapies for diabetes and their possible association with pancreatic cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

ENDO Seconds Call for Incretin Data
SAN FRANCISCO (MedPage Today) -- The Endocrine Society has joined its voice to the recent call for incretin drugmakers to release all patient-level data on their products, the group announced at its annual meeting. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 19, 2013 Category: Cardiology Source Type: news

Society Seconds Call for Incretin Data
SAN FRANCISCO (MedPage Today) -- The Endocrine Society has joined its voice to the recent call for incretin drugmakers to release all patient-level data on their products, the group announced at its annual meeting. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 19, 2013 Category: Cardiology Source Type: news